Clinical trial Phase 3 Interventional Ages 18 and up

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Run by Mirati Therapeutics Inc. · NCT04793958 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2026-01-16.

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Research outlook What's coming for Colorectal cancer: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment461 (actual)
SponsorMirati Therapeutics Inc.
Industry-sponsored
Drugs / interventionsMRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen
Locations419 sites (Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia and more)
Trial IDNCT04793958 on ClinicalTrials.gov

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
* Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.

Exclusion Criteria:

* Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
* Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
* Active brain metastasis

Where it's running

  • Local Institution - 010-855-E
    Alabaster, Alabama, United States
  • Local Institution - 010-855-B
    Bessemer, Alabama, United States
  • Local Institution - 010-855-D
    Birmingham, Alabama, United States
  • Local Institution - 010-855-A
    Birmingham, Alabama, United States
  • Local Institution - 010-855-F
    Birmingham, Alabama, United States
  • Local Institution - 010-855-C
    Birmingham, Alabama, United States
Show 44 more locations
  • Local Institution - 010-855
    Birmingham, Alabama, United States
  • Local Institution - 010-996
    Gilbert, Arizona, United States
  • Local Institution - 010-566
    Goodyear, Arizona, United States
  • Local Institution - 010-989
    Phoenix, Arizona, United States
  • Local Institution - 010-978
    Springdale, Arkansas, United States
  • Local Institution - 010-573
    Bakersfield, California, United States
  • Local Institution - 010-979C
    Chula Vista, California, United States
  • Local Institution - 010-980
    Fresno, California, United States
  • Local Institution - 010-851
    Fullerton, California, United States
  • Local Institution - 010-979A
    La Mesa, California, United States
  • Local Institution - 010-958A
    Los Angeles, California, United States
  • Local Institution - 010-958
    Los Angeles, California, United States
  • Local Institution - 010-551
    Los Angeles, California, United States
  • Local Institution - 010-847
    Newport Beach, California, United States
  • Local Institution - 010-563
    Redlands, California, United States
  • Local Institution - 010-979B
    San Diego, California, United States
  • Local Institution - 010-979D
    San Diego, California, United States
  • Local Institution - 010-979
    San Diego, California, United States
  • Local Institution - 010-982
    San Francisco, California, United States
  • Local Institution - 010-561
    Santa Monica, California, United States
  • Local Institution - 010-571
    Sylmar, California, United States
  • Local Institution - 010-574
    Torrance, California, United States
  • Local Institution - 010-570
    Whittier, California, United States
  • Local Institution - 010-872-H
    Aurora, Colorado, United States
  • Local Institution - 010-810
    Aurora, Colorado, United States
  • Local Institution - 010-872-A
    Boulder, Colorado, United States
  • Local Institution - 010-872-E
    Centennial, Colorado, United States
  • Local Institution - 010-872-C
    Colorado Springs, Colorado, United States
  • Local Institution - 010-872
    Denver, Colorado, United States
  • Local Institution - 010-872-B
    Denver, Colorado, United States
  • Local Institution - 010-872-J
    Lakewood, Colorado, United States
  • Local Institution - 010-872-F
    Littleton, Colorado, United States
  • Local Institution - 010-872-G
    Longmont, Colorado, United States
  • Local Institution - 010-872-I
    Pueblo, Colorado, United States
  • Local Institution - 010-872-D
    Thornton, Colorado, United States
  • Local Institution - 010-949
    Norwich, Connecticut, United States
  • Local Institution - 010-922-A
    Bonita Springs, Florida, United States
  • Local Institution - 010-922-D
    Bradenton, Florida, United States
  • Local Institution - 010-922-E
    Cape Coral, Florida, United States
  • Local Institution - 010-922
    Fort Myers, Florida, United States
  • Local Institution - 010-922-B
    Fort Myers, Florida, United States
  • Local Institution - 010-922-C
    Fort Myers, Florida, United States
  • Local Institution - 010-984-B
    Holiday, Florida, United States
  • Local Institution - 010-829
    Jacksonville, Florida, United States

+369 more sites. See ClinicalTrials.gov for the full list.

Study contacts

  • Principal investigator: Bristol-Myers Squibb — Bristol-Myers Squibb

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.